
	Where results make sense

Topic: Biocon

In the News (Fri 13 Nov 09)

Northern Trust

Marvin Harrison

Peter Chernin

Gary Locke

Match Play

Penelope Cruz

Mickey Rourke

AR Rahman

Danny Boyle

Hugh Jackman

	Biocon - Wikipedia, the free encyclopedia
		She achieved this status after Biocon went for an IPO in 2004.
		Biocon became only the second Indian company to cross a market capitalisation of one billion U.S. on the first day of listing.
		Biocon is the first Indian company to be approved by US FDA for the manufacture of pplovastatin, a cholesterol-lowering molecule
	en.wikipedia.org /wiki/Biocon (446 words)

	Biocon a good buy, but expensive: Analysts
		Biocon also has a patented fermentation process, which is a big plus as fermentation is one of the key enabling technologies in the manufacturing of pharmaceutical products.
		Biocon derives about 60 per cent of its revenues by catering to the market for the four statins -- lovastatin, simvastatin, pravastatin and atorvastatin that comprise the statin family.
		Biocon hopes to use the money from its IPO to further its expansion plans and set up its second fermentation and chemical synthesis plant to meet the increase in demand expected from the statins space.
	www.rediff.com /money/2004/mar/05biocon.htm (945 words)

	Biocon wins bid for acquiring Nobex Corporations assets
		Biocon Limited, Indias premier biotechnology company has announced that it had put up the winning bid for acquiring all the assets of Nobex Corporation, a drug development company specializing in a proprietary drug delivery system to enable oral delivery of peptide drugs.
		Biocon made an opening stalking horse bid of 3.5 million dollars to acquire the assets of Nobex before the auction and emerged as the final bidder with a total commitment, including the settlement with the creditors committee, of five million dollars and certain back-end royalties.
		Biocon believes that the future of the pharmaceutical industry lies in innovation and our focus on IP and technology will be a strong differentiator.
	news.webindia123.com /news/Articles/Business/20060329/291642.html (439 words)

	[No title] (Site not responding. Last check: 2007-10-14)
		According to Biocon officials, the drug is engineered to specifically target and block the epidermal growth factor receptor responsible for the proliferation of cancer cells.
		According to Biocon, monoclonal antibodies are emerging as the fastest-growing segment, especially in oncology and auto-immune diseases like rheumatoid arthritis, psoriasis, and lupus.
		Biocon has seen a decline in profit in the past year due to pricing pressure on generics and cholesterol-lowering drugs, or statins, which are the mainstay of the biotech firm.
	www.redherring.com /Article.aspx?a=16524&hed=Biocon+Plans+Cancer+Drug (362 words)

	Biocon Biopharma introduces 2 antibodies - Sify.com
		The Bangalore-based Biocon Biopharmaceuticals, a joint venture between Biocon Ltd and Cuban pharmaceutical firm Cimab SA (CIMAB), launched an h-T1, a humanised anti-CD 6, targeting immuno-suppressive monoclonal antibody for T-cell Lymphoma, Rheumatoid Arthritis and Psoriasis and q-T3, a chimeric anti-CD3 targeting immuno-suppressive monoclonal antibody for organ transplant.
		Biocon said, in a statement, a phase IIB 4 arm clinical trial for h-R3 is about to commence to evaluate efficacy in squamous cell Carcinoma of solid head and neck tumors.
		Biocon holds a majority stake of 51 per cent in Biocon Biopharma while the rest is held by Cimab.
	sify.com /finance/equity/fullstory.php?id=13502492 (309 words)

	The Hindu : National : Biocon close to developing oral insulin
		BANGALORE: Pharma major Biocon is close to developing an oral insulin that will free millions of insulin-dependent diabetic patients from the misery of taking insulin shots three times a day for the rest of their lives.
		Biocon has commenced pre-clinical studies in animals to evaluate the safety and efficacy of the oral insulin molecule IN 105 being developed in conjunction with a Scottish research institute, Hannah, and its offspring, FFAST Solutions.
		Biocon was discussing with two pharma majors for licensing rights though many have lined up.Insulin is most beneficial when it is given as soon as a person is afflicted with diabetes.
	www.hindu.com /2005/07/21/stories/2005072102961300.htm (411 words)

	Biocon plans new unit for Cuban JV
		The facility, in which Biocon will invest Rs 125 crore (Rs 1.25 billion), is expected to begin commercial production of Mab products in 2006.
		Biocon holds a majority stake of 51 percent in BBPL, while the rest is held by Cimab.
		Recently the Biocon board had given a preliminary approval to finance capital expenditure of up to Rs 85 crore (Rs 850 million) for the joint venture.
	www.rediff.com /money/2004/mar/15biocon.htm (331 words)

	Forbes.com: INTERVIEW-Biocon gears up for India's first biotech IPO (Site not responding. Last check: 2007-10-14)
		Biocon is India's largest biotech company with an estimated revenue of 5.5 billion rupees ($122 million) and net profit of 1.2 billion to 1.3 billion rupees in the year to March 2004, up from 2.83 billion rupees and a profit of 422 million a year earlier.
		Biocon aims to have $1.0 billion in revenue within a decade, with solid growth expected in the next five years.
		Biocon aims to use the IPO to raise its profile and fund a 4.13 billion rupee expansion of cholesterol-lowering statin manufacturing facilities at an 80-acre (32-hectare) campus on the outskirts of Bangalore.
	www.forbes.com /home_asia/newswire/2004/02/13/rtr1259974.html (681 words)

	domain-B : Indian business : companies : The Biocon story
		Such is the buzz surrounding Biocon and the biotechnology industry that within minutes of opening, the Biocon scrip surged to Rs500, zooming past the Rs.
		Biocon was named after Mazumdar's Irish joint venture partner, who partly funded the company and whose stake was later acquired by Unilever.
		Biocon, besides making enzymes and drugs to fight diabetes, cancer and cholesterol, has separate units offering contract research and clinical trial services for global clients.
	www.domain-b.com /companies/companies_b/biocon/20040507_biocon_story.html (798 words)

	Equitymaster.com : Related Views on News
		Biocon has announced mixed results for the fourth quarter and year ended March 2006.
		Biocon is India's largest biotechnology company with presence in biopharmaceuticals, enzymes, custom research and clinical research.
		Biocon held a conference call post the declaration of its results for the second quarter and half year ended September 2005 to discuss its quarterly performance and growth prospects for the future.
	www.equitymaster.com /f-detail.ASP?Symbol=BICN (587 words)

	About BIOCON: Biopharmaceutical and Biotechnology Enterprise
		At Biocon, our success has been our ability to develop innovative technologies and products and to rapidly leverage them to adjacent domains.
		November 29, 1978, Biocon's founding day, marked the beginning of a biorevolution in India.
		Biocon at a glance - general information, location, key facts, products and services.
	www.biocon.com /biocon_aboutus.asp (251 words)

	Equitymaster.com : Biocon: Clinical performance
		Biocon started as an enzymes (organic chemicals used in fermentation process) manufacturer and leveraged its expertise in fermentation to evolve into an integrated bio-pharmaceutical company with expertise across the value chain, with strengths in microbial techniques, manufacturing and marketing.
		Biocon has increased its employee strength and increased the capacity of Syngene (its custom research subsidiary).
		Biocon's margins have been high owing to very high capacity utilization and lower competition in the biopharmaceutical space.
	www.equitymaster.com /detail.asp?date=10/20/2004&story=3 (622 words)

	The Hindu Business Line : Biocon launches bio insulin
		Biocon is also the first Indian insulin producer to submit a DMF (drug master file) to the USFDA.
		Biocon becomes the newest player in the country's growing insulin segment that is dominated by MNCs Novo Nordisk and Eli Lilly; and the second Indian entrant after Wockhardt, which launched its r-DNA product Wosulin last year.
		Over the past four years, Biocon has invested Rs 55 crore in its insulin plant — said to be the Asia's largest and capable of meeting five times the country's insulin demand - and another Rs 20 crore in R&D of the project.
	www.thehindubusinessline.com /2004/11/11/stories/2004111101520300.htm (484 words)

	The Hindu Business Line : Biocon: Hold
		Biocon has in place an agreement to supply insulin to the global major, Bristol-Myers Squibb (BMS), for an inhaled product that the latter is developing; Biocon has also received an upfront payment (the quantum has not been undisclosed) from BMS, which has not been reflected in the latest quarter.
		Biocon also has announced a partnership with Nobex Corporation, US, for developing a form of oral insulin; this would be a New Drug Application candidate and its proof of concept is likely to be established in a little over two years from now.
		The monoclonal antibody that Biocon, in collaboration with CIMAB of Cuba, is developing to treat head and neck cancer, is likely to hit the Indian market by the end of next year.
	thehindubusinessline.com /iw/2004/12/05/stories/2004120500530900.htm (636 words)

	Oral insulin: Biocon seeks FDA nod
		Biotech major Biocon will file an application with the US Federal Drug Administration to begin clinical trials for oral insulin, which, it says, would be the world's first insulin that could be consumed orally.
		Biocon has already done the pre-clinical animal toxicity studies of the oral insulin, for which it has tied up with US pharma start-up Nobex and will jointly file by December, the Integrated new drug application with the US FDA, Biocon chairman and managing director, Kiran Mazumdar Shaw said in Bangalore on Wednesday.
		Biocon already has a recombinant human insulin that is sold to diabetic patients in India.
	inhome.rediff.com /money/2005/apr/20biocon.htm (163 words)

	Getti‘Biocon is my only child’
		When Kiran Mazumdar-Shaw started Biocon in 1978 from a rented garage with Rs 10,000 in the bank, not many knew what biotechnology was all about.
		And so when Biocon, which makes enzymes, statins and other bioproducts, went public last week, the issue was oversubscribed 32 times.
		By the end of the day, she was India’s richest woman entrepreneur at Rs 1,887 crore — worth of her 39 per cent stake in Biocon.
	www.indiainitiative.com /articles_biocon.htm (338 words)

	Biopharmaceutical and Biotechnology Company \| Drug Discovery & Development - BIOCON
		Biocon to file for approval of cancer drug
		Biocon is an integrated biotechnology enterprise focused on the development of biopharmaceuticals.
		Biocon is committed to finding biotechnology solutions for customers across the world.
	www.biocon.com (254 words)

	Biocon (Site not responding. Last check: 2007-10-14)
		Syngene: A subsidiary of Biocon, Syngene provides customised RandD services to the pharmaceutical and biotechnology sectors, on a strong platform of confidentiality and intellectual property protection.
		Established in the year 2000 as a Biocon subsidiary, we set up India's first CAP (College of American Pathologists) accredited Central Reference Laboratory with clinical specialisations in biochemistry, haematology, histopathology and microbiology.
		Today, Biocon together with Syngene and Clinigene employs over 1200 highly qualified biologists, chemists, computer scientists, medical practitioners, pharmacologists, engineers, financial, legal, marketing analysts and general administrators.
	www.naukri.com /gpw/biocon (217 words)

	Biocon aims to buy assets from bankrupt partner - Pharmaceutical Business Review (Site not responding. Last check: 2007-10-14)
		Preclinical trials have been completed and Biocon previously said that it planned to apply for regulatory clearance to begin human trials in India around the middle of 2006.
		Biocon had also announced its intention to file an investigational new drug application (IND) with the FDA by the same time.
		Biocon has already invested $5.8 million in Nobex - $1 million as common stock and the rest in convertible loans.
	www.pharmaceutical-business-review.com /article_news.asp?guid=4D0FA5BB-52A4-4A49-A3B4-C8CD8C3415BB (389 words)

	Biocon to conduct trials for oral insulin : HindustanTimes.com (Site not responding. Last check: 2007-10-14)
		Biocon to conduct trials for oral insulin : HindustanTimes.com
		Biocon to conduct clinical trials for oral insulin
		India's leading biotech firm Biocon plans to conduct clinical trials for oral insulin after securing clearance from the US Federal Drug Administration (FDA).
	www.hindustantimes.com /news/181_1329064,0050.htm (249 words)

	The Hindu : Business : Biocon net jumps 42 p.c.
		Announcing the results, the Biocon Chairperson and Managing Director, Kiran Mazumdar Shah, said the company would maintain the current levels of operating margin.
		The company's vision was to be an integrated biopharmaceutical enterprise of global distinction and would soon be the first company, globally, to manufacture human insulin using a Pichia expression system.
		In addition, Biocon is positioned to be India's largest producer of human insulin and India's first company to set up commercial production of monoclonal antibodies.
	www.hindu.com /2005/04/21/stories/2005042105101800.htm (374 words)

	Biocon considers overseas listing to aid global buys- The Economic Times (Site not responding. Last check: 2007-10-14)
		KOLKATA: Biocon, often known as the ‘Infosys of the biotech realm’, is mulling an overseas listing in the near future.
		There are no decisions yet on the actual timing or size of such an overseas flotation, but Biocon’s chairman and MD Kiran Mazumdar-Shaw isn’t ruling out a US listing a few months down the line to complement the company’s plans to acquire global biotech firms.
		At present, Biocon’s RandD budget is roughly 15% of its Rs 728-crore annual revenue.
	economictimes.indiatimes.com /articleshow/1219871.cms (395 words)

	newsobserver.com \| Nobex drug company in bankruptcy
		Biocon, India's leading biotechnology company and a Nobex investor and partner, has offered to buy the company's intellectual property for $3.5 million.
		Biocon and Nobex have partnerships to develop two experimental drugs, the insulin pill and a pill to treat cardiovascular disease.
		Biocon will take over Nobex's technology and drug development pipeline, unless another bidder emerges that is willing to pay more.
	www.newsobserver.com /104/story/374771.html (631 words)

	[No title]
		Born out of Germany´s "BioRegio" competition in 1996 BioCon Valley represents an interdisciplinary network in the field of modern life sciences and health care.
		BioCon Valley´s main offices are located in Greifswald and Rostock, we have affiliate offices in Groß Lüsewitz and Teterow.
		BioCon Valley is strongly engaged in ScanBalt, an international life science platform around the Baltic Sea.
	www.bcv.org /hosting/bcv/website_en.nsf/urlnames/aboutus_EN?OpenDocument&mnu=aboutus (136 words)

	Kruger (Site not responding. Last check: 2007-10-14)
		BioCon is a low temperature, indirect convection, closed loop belt dryer system.
		Also, the drying air is recirculated in an enclosed cycle; therefore, no drying air is released to the surroundings.
		BioCon operating temperatures never exceed 350°F (and that is only during the first stage when the sludge contains considerable moisture)
	www.krugerusa.com /Pages/Products/BioCon.htm (260 words)

	Nobex (Site not responding. Last check: 2007-10-14)
		Based in Bangalore, India, Biocon is a publicly listed biopharmaceuticals company with world-class manufacturing capabilities and with a market capitalization approximating $US1.2 billion.
		Biocon operates FDA licensed and ISO 9001 qualified manufacturing facilities specializing in the manufacture of statins (cholesterol-lowering agents) and insulin in proprietary yeast expression systems.
		The structure of the second arrangement is similar to that of the first for oral insulin.
	www.nobexcorp.com /partner/current.php (171 words)

	Biocon gets into lifestyle drug market- The Times of India (Site not responding. Last check: 2007-10-14)
		The division, according to Biocon officials, is pinning its hopes on cardio-diabetes products to develop its business further.
		There is a ready global market waiting to be tapped in these segments, and Indian biotech companies, with their strong army of researchers, were best equipped to exploit it.
		Biocon is planning a huge human resources drive for Biocon Health, though it is not clear yet as to how many employees they will add at the end of it.
	timesofindia.indiatimes.com /articleshow/msid-796761,prtpage-1.cms (392 words)

Try your search on: Qwika (all wikis)